Etrolizumab for Ulcerative Colitis (For patients who have previously used anti-TNFs)

  • Injection under the Skin
  • Limited to 800 patients
  • 1 Location

This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have failed an anti-TNF therapy (e.g. Remicade, Humira, etc.) previously.

Eligibility Checklist

You may be eligible to participate if you meet the following criteria:

  • Ages 18 - 80
  • Male or Female
  • Diagnosed with ulcerative colitis
  • Moderately to severely active ulcerative colitis (i.e. not in remission)
  • Have previously used one or two anti-TNF therapy(ies) within the previous 5 years.
  • Have not previously been treated with Entyvio (vedolizumab)
See if you're eligible ›

How You Can Participate

This study is currently accepting candidates. You would receive medical care from Dr. Brian Bressler at GI Research Institute. Answer a few questions to see if you can participate ›

Frequently Asked Questions

How much does it cost?
The treatment and doctor visits are free.
Are traveling expenses covered?
Travel expenses will generally be covered.
I have more questions, who do I ask?
Contact us 1-800-794-6031 or


Here's a timeline of what you can expect:

Fill out quiz

Step 1: Online Pre-screener

Find out if you are a match by answering a few online questions.
Stay Informed ›


Step 2: Phone Call with Care Coordinator

Speak with our Care Team specialist to confirm your candidacy.

Baseline appointment

Step 3: Screening Appointment

If you are eligible to continue, you will be given an appointment date and time to come to the clinic for a screening visit.